Celcuity Stock Tanks 17.6% on Late Q3 Cancer Drug Launch; Pomerantz Investigates

For healthcare investors, Celcuity’s sudden 17.6% nosedive following a pivotal FDA approval sounds a familiar alarm: even triumphant regulatory milestones can be overshadowed by execution delays. The late Q3 2026 launch timeline for gedatolisib—a breast cancer therapy long in the pipeline—has sparked not only a shareholder lawsuit investigation but also fresh scrutiny of biotech companies’ ability to transition from clinical success to commercial readiness. As Pomerantz digs into potential misrepresentations, the episode underscores the high-stakes interplay between FDA clearance, market expectations, and litigation risk in the life sciences sector.

Starting July 16, 2026, Pomerantz LLP launched simultaneous investigations into five companies—Pentair, Celcuity, Wix, IBM, and FirstSun Capital Bancorp—targeting potential securities fraud after each disclosed disappointing news. The cluster of alerts underscores a recurring cycle in public markets: unexpected operational or financial shortfalls trigger steep stock declines, which in turn draw the attention of class-action law firms seeking to represent institutional and retail investors. While the investigations remain preliminary, the specific events that spurred them reveal deep-seated challenges at each company, offering a case study in risk management and disclosure practices.

“

FirstSun Capital Bancorp, a smaller regional bank, saw its stock fall 7.5% to $35.08 after disclosing a severe credit event: a $22 million fraud-related loan charge-off was embedded in total expected charge-offs of $42-43 million.

Pentair announced preliminary second-quarter 2026 results that sent its stock down 15% to $64.33. The company reported sales of about $930 million, a 17% decline versus its earlier guidance of approximately 1% growth, attributing the miss to “adverse impact of Pool channel inventory.” Full-year guidance was slashed from an expected 2%-4% increase to a 4%-7% decline, with the CFO also departing. Investors were blindsided by the severity of the channel destocking, raising questions about whether Pentair had previously signaled these inventory headwinds.

Celcuity’s investors were dealt a blow when the biotech finally secured FDA approval for Revtorpyk (gedatolisib), a breast cancer therapy, but disclosed that commercial launch would not occur until late Q3 2026—considerably later than the market anticipated. Stifel and Leerink analysts quickly noted the disconnect with prior company commentary on launch readiness. The stock tumbled 17.6% to $91.51 on July 15, reflecting the harsh reality that in biotech, regulatory approval is only half the battle; timely execution is paramount. The delay may also raise concerns about manufacturing or supply chain preparedness, a common pain point for emerging drug companies.

Wix.com’s first-quarter 2026 earnings revealed a sharp erosion in its competitive position. The company posted lower-than-expected revenue and margins, largely due to professional developers migrating to rival AI tools and the shortcomings of its own Wix Harmony platform. Management’s frank admission that it had fallen behind “the workflow and the needs of” professional developers—after previously touting the platform—sparked a 27% one-day crash to $55.32 on May 13, its worst in years. This collapse highlights the disruptive threat AI poses to established SaaS platforms that fail to innovate quickly.

IBM’s second-quarter 2026 miss was perhaps the most dramatic, with shares plunging 25.21% to $217.07 on July 14. The technology giant blamed a “shortfall in our Z performance and the associated software stack, primarily in Transaction Processing,” and acknowledged it had “faltered” in closing large deals. The scale of the miss and management’s contrite tone suggest the company misread demand cycles and execution critical for its mainframe and software business, a segment long viewed as a stable cash generator. The sell-off erased billions in market capitalization and has put leadership under immediate pressure.

FirstSun Capital Bancorp, a smaller regional bank, saw its stock fall 7.5% to $35.08 after disclosing a severe credit event: a $22 million fraud-related loan charge-off was embedded in total expected charge-offs of $42-43 million. The bank also anticipated a $40-41 million provision for credit losses, signaling broader asset-quality deterioration. This disclosure, coming on July 9, raises red flags about FirstSun’s underwriting controls and has attracted Pomerantz’s scrutiny.